Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: A case report

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 3, 1996, Pages 267-272

  Ekstrøm, Per O ^a   Andersen, Anders ^a   Saeter, Gunnar ^a   Giercksky, Karl E ^a   Slørdal, Lars ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Natl Inst of Forensic Toxicology   (Norway)

Author keywords

7 Hydroxymethotrexate; Methotrexate; Microdialysis; Tumor

Indexed keywords

7 HYDROXYMETHOTREXATE; CISPLATIN; CLINDAMYCIN; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE;

ADULT; ARTICLE; CASE REPORT; DRUG TUMOR LEVEL; FEMUR CONDYLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MICRODIALYSIS; PRIORITY JOURNAL; REGIONAL PERFUSION;

EID: 0031060352     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050571     Document Type: Article

References (18)

1. Ackland SP, Schilsky RL (1987) High-dose methotrexate: a critical reappraisal. J Clin Oncol 5: 2017
2. Benveniste H, Huttemeier PC (1990) Microdialysis theory and application. Prog Neurobiol 35: 195
3. Ekstrøm PO, Andersen A, Warren DJ, Giercksky KE, Slørdal L (1994) Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. Cancer Chemother Pharmacol 34: 297
4. Ekstrøm PO, Andersen A, Warren DJ, Giercksky KE, Slørdal L (1995) Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model. Cancer Chemother Pharmacol 36: 283
5. Ekstrøm PO, Andersen A, Warren DJ, Giercksky KE, Slørdal L (1996) Determination of extracellular methotrexate tissue levels by microdialysis in a rat model. Cancer Chemother Pharmacol 37: 398
6. Ferrari S, Sassoli V, Orlandi M, Strazzari S, Puggioli C, Battistani A, Bacci G (1993) Serum methotrexate (MTX) concentration and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 5: 135
7. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U (1994) Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12: 1443
8. Jacobs SA, Stoller RG, Chabner BA, Johns DG (1977) 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 57: 534
9. Jain RK (1987) Transport of molecules in tumor interstitium: a review. Cancer Res 47: 3039
10. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48: 2641
11. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094
12. Sæter G, Alvegaard TA, Elomaa I, Stenwig AE, Holmström T, Solheim ØP (1991) Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9: 1766
13. Slørdal L, Prytz PS, Pettersen I, Aarbakke J (1986) Methotrexate measurements in plasma: comparison of enzyme multiplied immunoassay technique, TDx fluorescence polarization immunoassay, and high pressure liquid chromatography. Ther Drug Monit 8: 368
14. Slørdal L, Sager G, Aarbakke J (1988) Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexute the culprit? Lancet I: 591
15. Slørdal L, Sager G, Huseby NE, Aarbakke J (1988) Distribution of 7-hydroxy-methotrexate in human blood. J Pharm Pharmacol 40: 50
16. Slørdal L, Sager G, Jœger R, Aarbakke J (1988) Interactions with the protein binding of 7-hydroxy-methotrexate in human serum in vitro. Biochem Pharmacol 37: 607
17. Ståhle L, Alm C, Ekquist B, Lundquist B, Tomson T (1996) Monitoring free extracellular valproic acid by microdialysis in epileptic patients. Ther Drug Monit 18: 14
18. Steele WH, Lawrence JR, Stuart JF, McNeill CA (1981) The protein binding of methotrexate in the serum of patients with neoplastic disease. Cancer Chemother Pharmacol 7: 61